NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Centers for Disease Control and Prevention
Conditions: Pulmonary Tuberculosis
Interventions: rifapentine, rifapentine 10 mg/kg, rifapentine 15 mg/kg, rifapentine 20 mg/kg
Countries: United States, Brazil, Canada, South Africa, Spain, Uganda
This Phase 2, multicenter, open-label clinical trial evaluated the antimicrobial activity and safety of rifapentine-containing regimens during the intensive phase of pulmonary tuberculosis treatment. Participants were randomized to receive either a standard rifampin-based regimen (RHZE) or a rifapentine-substituted regimen (PHZE). An extension study evaluated higher daily doses of rifapentine (10, 15, and 20 mg/kg). The primary endpoint was sputum culture conversion at 8 weeks. Secondary outcomes included time to culture conversion, safety, and treatment discontinuation.
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: 1. Suspected pulmonary tuberculosis with acid-fast bacilli in a stained smear of expectorated or induced sputum. 2. Willingness to have HIV testing performed, if HIV serostatus is not known or if the last documented negative HIV test was more than 3 months prior to enrollment. 3. 5 (five) or fewer days of multidrug therapy for tuberculosis disease in the 6 months preceding initiation of study drugs. 4. 7 (seven) or fewer days of fluoroquinolone therapy in the 30 days preceding initiation of study drugs. 5. Age \>= 18 years 6. Karnofsky score of at least 60 (requires occasional assistance but is able to care for most of his/her needs; see Appendix B) 7. Signed informed consent 8. Women of child-bearing potential must agree to practice an adequate (barrier) method of birth control or to abstain from heterosexual intercourse during study therapy. 9. Laboratory parameters done within 14 days prior to, enrollment: * Serum or plasma alanine aminotransferase (ALT) activity ≤ 3 times the upper limit of normal * Serum or plasma total bilirubin level ≤ 2.5 times the upper limit of normal * Serum or plasma creatinine level ≤ 2 times the upper limit of normal * Complete blood count with hemoglobin level of at least 7.0 g/dL * Complete blood count with platelet count of at least 100,000/mm3 * Negative pregnancy test (women of childbearing potential) Exclusion Criteria: 1. Pregnant or breast-feeding 2. Known intolerance or allergy to any of the study drugs 3. Concomitant disorders or conditions for which isoniazid (INH), rifamycins, pyrazinamide (PZA), or ethambutol (EMB) are contraindicated. These include severe hepatic damage, acute liver disease of any cause, and acute uncontrolled gouty arthritis. 4. Current or planned therapy, during the intensive phase of TB therapy, with combination antiretroviral therapy for HIV, or with cyclosporine or tacrolimus. Cyclosporine and tacrolimus have unacceptable interactions with rifamycins. 5. Pulmonary silicosis 6. Central nervous system TB 7. Weight \< 40 kg or \> 85 kg
- Little Rock, Arkansas, United States
- Los Angeles, California, United States
- Los Angeles, California, United States
- San Diego, California, United States
- San Francisco, California, United States
- Denver, Colorado, United States
- Washington D.C., District of Columbia, United States
- Atlanta, Georgia, United States
- Chicago, Illinois, United States
- Chicago, Illinois, United States
- Hines, Illinois, United States
- Baltimore, Maryland, United States
- Boston, Massachusetts, United States
- Newark, New Jersey, United States
- New York, New York, United States
- New York, New York, United States
- Durham, North Carolina, United States
- Nashville, Tennessee, United States
- Nashville, Tennessee, United States
- Fort Worth, Texas, United States
- Houston, Texas, United States
- San Antonio, Texas, United States
- Seattle, Washington, United States
- Rio de Janeiro, Brazil
- Winnepeg, Manitoba, Canada
- Montreal, Quebec, Canada
- Durban, KwaZulu-Natal, South Africa
- Barcelona, Spain
- Kampala, Uganda